Why VC legend Bob Nelsen is making the biggest initial bet of his 37-year career on Xaira

Andrew Dunn

Senior Biopharma Correspondent

Ryan Cross

Senior Science Correspondent

In the 37 years since co-founding ARCH Venture Partners, Bob Nelsen has built a reputation for placing head-turning bets on ideas that carry huge amounts …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Why VC legend Bob Nelsen is making the biggest initial bet of his 37-year career on Xaira

Andrew Dunn

Senior Biopharma Correspondent

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Trump blog: Judge extends nationwide block on NIH payment cuts

RFK Jr. readies review of childhood vaccine schedule after pledging not to

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Why VC leg­end Bob Nelsen is mak­ing the biggest ini­tial bet of his 37-year ca­reer on Xaira

Senior Biopharma Correspondent

Senior Science Correspondent

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Why VC legend Bob Nelsen is making the biggest initial bet of his 37-year career on Xaira